曲美他嗪对肾功能不全患者冠脉介入术后造影剂肾病的预防作用

发布时间：2018-07-16 11:19

【摘要】：目的研究曲美他嗪在肾功能不全患者冠脉介入术后,预防造影剂肾病(CIN)的疗效。方法纳入160例行冠脉介入术的肾功能不全患者,采用随机数字表法分为两组:对照组和曲美他嗪组,均予水化治疗。曲美他嗪组患者术前48 h和术后7 d予曲美他嗪片20 mg/次,每天3次。监测术前1 d和术后3 d血清肌酐(SCr)和胱抑素C(Cys C)水平,并随访1年。结果 (1)术后24 h、48 h:对照组SCr和CysC较基线水平显著升高(P0.05);曲美他嗪组SCr和CysC与基线水平相比,差异无统计学意义(P0.05);曲美他嗪组SCr和CysC水平显著低于对照组(P0.05)。(2)曲美他嗪组CIN发生率显著低于对照组(P=0.034)。(3)Kaplan-Meier分析发现,随访1年曲美他嗪组不良事件发生率显著低于对照组(P=0.003)。结论曲美他嗪在行冠脉介入术的肾功能不全患者中,可有效预防CIN发生。
[Abstract]:Objective to study the effect of trimetazidine on preventing contrast agent nephropathy (cin) after coronary intervention in patients with renal insufficiency. Methods 160 patients with renal insufficiency underwent coronary intervention were randomly divided into two groups: control group and trimetazidine group. Patients in trimetazidine group were treated with trimetazidine tablets for 20 mg/, 48 hours before operation and 7 days after operation, three times a day. Serum creatinine (SCR) and cystatin C (Cys C) levels were monitored 1 day before and 3 days after operation, and followed up for 1 year. Results (1) 24 hours after operation, the levels of SCR and CysC in the control group were significantly higher than those in the baseline group (P0.05), and the levels of SCR and CysC in the trimetazidine group were significantly higher than those in the baseline level. The levels of SCR and CysC in trimetazidine group were significantly lower than those in control group (P0.05). (2). The incidence of cin in trimetazidine group was significantly lower than that in control group (P0. 034). (3) Kaplan-Meier analysis showed that the incidence of adverse events in trimetazidine group was significantly lower than that in control group (P0. 003). Conclusion trimetazidine can effectively prevent the occurrence of cin in renal insufficiency patients undergoing coronary intervention.
【作者单位】：民航总医院北京大学民航临床医学院;
【基金】：首都临床特色应用研究基金项目(编号:Z141107002514139)
【分类号】：R541.4;R692

【相似文献】